生命科学软件公司Certara（CERT）周四盘中股价大涨7.87%，尽管公司最新公布的季度业绩未达预期。这一显著涨幅引发了市场广泛关注。
根据公司发布的2025财年第二季度财报，Certara调整后每股收益为0.07美元，低于分析师预期的0.10美元。季度营收达到1.0457亿美元，同比增长12.1%，略低于分析师预期的1.0503亿美元。尽管公司报告当季净亏损197万美元，但调整后EBITDA达到3190万美元，反映出公司运营状况有所改善。
分析人士指出，尽管短期业绩略显疲软，但投资者似乎更关注Certara的长期发展前景。目前分析师对该公司股票的平均评级为"买入"，12个月目标价中位数为15.00美元，较近期收盘价高出约36.5%。这种积极的分析师展望可能是推动股价上涨的主要因素，投资者可能认为当前价格提供了较好的入场机会。Certara在生命科学软件领域的领先地位和持续增长的市场需求，使得投资者对其未来发展保持乐观态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.